Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReT01 ACT Injection in Advanced Cervical Cancer
CTR20260066Phase 2Active
- Sponsor
- Anweisen Biomedical
- Start
- Mar 2026
- Countries
- 1
01
Overview
A Phase 2 trial of ReT01 ACT in Cervical Cancer (CC), sponsored by Anweisen Biomedical. Started Mar 2026; status: active.
02
Drugs
ReT01 ACT
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20260066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260066.